Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Alirocumab,Atorvastatin,Simvastatin,Fluvastatin,Pravastatin,Lovastatin,Rosuvastatin Calcium,Ezetimibe,Cholestyramine,Niacin,Fenofibrate,Omega-3
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase III
Sponsor : Regeneron Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Antibody
Upfront Cash : Inapplicable
April 27, 2018
Lead Product(s) : Alirocumab,Atorvastatin,Simvastatin,Fluvastatin,Pravastatin,Lovastatin,Rosuvastatin Calcium,Ezetimibe,Cholestyramine,Niacin,Fenofibrate,Omega-3
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Sponsor : Regeneron Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Alirocumab,Rosuvastatin Calcium,Atorvastatin,Simvastatin,Pravastatin,Lovastatin,Fluvastatin,Ezetimibe,Cholestyramine,Niacin,Fenofibrate,Omega-3
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase III
Sponsor : Regeneron Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Antibody
Upfront Cash : Inapplicable
April 27, 2018
Lead Product(s) : Alirocumab,Rosuvastatin Calcium,Atorvastatin,Simvastatin,Pravastatin,Lovastatin,Fluvastatin,Ezetimibe,Cholestyramine,Niacin,Fenofibrate,Omega-3
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Sponsor : Regeneron Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Alirocumab,Atorvastatin,Rosuvastatin Calcium,Fenofibrate,Bezafibrate,Ezetimibe
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase IV
Sponsor : Regeneron Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Antibody
Upfront Cash : Inapplicable
December 07, 2016
Lead Product(s) : Alirocumab,Atorvastatin,Rosuvastatin Calcium,Fenofibrate,Bezafibrate,Ezetimibe
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase IV
Sponsor : Regeneron Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Alirocumab,Ezetimibe,Cholestyramine,Fenofibrate,Omega-3,Niacin
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase II
Sponsor : Regeneron Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Antibody
Upfront Cash : Inapplicable
September 07, 2016
Lead Product(s) : Alirocumab,Ezetimibe,Cholestyramine,Fenofibrate,Omega-3,Niacin
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase II
Sponsor : Regeneron Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Alirocumab,Atorvastatin,Ezetimibe,Bezafibrate,Fenofibrate
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase III
Sponsor : Regeneron Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Antibody
Upfront Cash : Inapplicable
October 22, 2015
Lead Product(s) : Alirocumab,Atorvastatin,Ezetimibe,Bezafibrate,Fenofibrate
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Sponsor : Regeneron Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Alirocumab,Ezetimibe,Fenofibrate
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase III
Sponsor : Regeneron Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Antibody
Upfront Cash : Inapplicable
December 30, 2013
Lead Product(s) : Alirocumab,Ezetimibe,Fenofibrate
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Sponsor : Regeneron Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable